Merck & Company Inc (MRK)vsZhengye Biotechnology Holding Limited Ordinary Shares (ZYBT)
MRK
Merck & Company Inc
$120.79
-1.42%
HEALTHCARE · Cap: $285.64B
ZYBT
Zhengye Biotechnology Holding Limited Ordinary Shares
$0.83
+0.06%
HEALTHCARE · Cap: $39.34M
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 56420% more annual revenue ($65.77B vs $116.36M). MRK leads profitability with a 13.6% profit margin vs -60.0%. MRK earns a higher WallStSmart Score of 50/100 (D+).
MRK
Hold50
out of 100
Grade: D+
ZYBT
Avoid26
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-49.3%
Fair Value
$80.88
Current Price
$120.79
$39.91 premium
Intrinsic value data unavailable for ZYBT.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 38.6%
Generating 2.9B in free cash flow
Reasonable price relative to book value
Areas to Watch
Premium valuation, high expectations priced in
4.9% revenue growth
Elevated debt levels
Weak financial health signals
Smaller company, higher risk/reward
Weak financial health signals
ROE of -25.2% — below average capital efficiency
Revenue declined 40.9%
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bull Case : ZYBT
The strongest argument for ZYBT centers on Price/Book.
Bear Case : MRK
The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.
Bear Case : ZYBT
The primary concerns for ZYBT are Market Cap, Piotroski F-Score, Return on Equity.
Key Dynamics to Monitor
MRK profiles as a value stock while ZYBT is a turnaround play — different risk/reward profiles.
MRK is growing revenue faster at 4.9% — sustainability is the question.
MRK generates stronger free cash flow (2.9B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
MRK scores higher overall (50/100 vs 26/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Zhengye Biotechnology Holding Limited Ordinary Shares
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Zhengye Biotechnology Holding Limited (Ticker: ZYBT) is an innovative biotechnology firm focused on the development and commercialization of advanced biopharmaceutical products. The company leverages its proprietary technologies and a diverse product pipeline to address critical medical needs, positioning itself strategically to enhance treatment outcomes across multiple therapeutic areas. With a robust commitment to research and development, ZYBT aims to drive significant growth and deliver substantial value to its investors, while maintaining a strong emphasis on quality and innovation within the dynamic biotechnology landscape.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?